BURLINGTON, Mass.--(Type 2 Diabetes in South Korea, market growth will be fueled by the increasing use of DPP-IV inhibitors, GLP-1 receptor agonists and insulin analogues as well as the introduction of the novel SGLT-2 inhibitor drug class. As in the major Western markets, the biguanide metformin is and will remain the leading option for the treatment of type 2 diabetes in South Korea owing to its low cost and long-term physician familiarity.)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the type 2 diabetes therapeutic market in South Korea will grow 11 percent annually from $330 million in 2011 to more than $550 million in 2016. According to
“South Korean physicians prefer newly-launched DDP-IV inhibitors over older OAAs, such as sulfonylureas, meglitinides and AGIs, due to their improvement on glycemic control without the risk of hypoglycemia”
The analysis also finds that changes in medical practice, specifically increased prescription of DPP-IV inhibitors, will help drive market growth in this region. DPP-IV inhibitors such as Merck’s Januvia and Janumet – the top two multinational corporation brands in the market – have been the top-selling drug class for the treatment of type 2 diabetes. This class is most often prescribed as a second-line approach, while GLP-1 receptor agonists are considered for third-line or later. The GLP-1 receptor agonist drug class – including Novo Nordisk’s Victoza and Amylin/Alkermes’s Bydureon – is forecasted to earn the second highest sales in the market over the next five years.
“South Korean physicians prefer newly-launched DDP-IV inhibitors over older OAAs, such as sulfonylureas, meglitinides and AGIs, due to their improvement on glycemic control without the risk of hypoglycemia,” said Decision Resources Analyst Jing Wu, M.S., M.B.A. “Branded DPP-IV inhibitors are better priced than these older agents and enjoy patent exclusivity throughout our study period. The increasing prescription of this drug class will lead to greater expenditure on antidiabetic agents in South Korea.”
The new report features extensive primary research with more than 100 South Korean physicians as well as a market outlook by drug and class through 2016 and type 2 diabetes epidemiology through 2021.
About Emerging Markets Reports
Decision Resources is the first and only company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians’ practices.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.